Related Experiment Video

Updated: Apr 26, 2026

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
08:00

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Published on: April 11, 2018

9.9K

Physical-capacity-related genetic polymorphisms in children with cystic fibrosis

Thomas Yvert1, Catalina Santiago, Elena Santana-Sosa

  • 1School of Doctorate Studies and Research, Universidad Europea de Madrid, Madrid, Spain.

Pediatric Exercise Science
|July 23, 2014
PubMed

Insights

Genetic factors influencing physical capacity (PC) in cystic fibrosis (CF) children were studied. The examined gene polymorphisms showed no significant impact on PC or health outcomes in CF patients.

Area of Science:

  • Genetics
  • Pediatrics
  • Pulmonology

Background:

  • Physical capacity (PC) is linked to mortality risk in cystic fibrosis (CF) patients.
  • PC is influenced by genetic factors, necessitating investigation into specific polymorphisms.
  • Understanding these genetic links can inform strategies for managing CF-related health outcomes.

Purpose of the Study:

  • To investigate the association between specific genetic polymorphisms and physical capacity (PC) and related health phenotypes in children with CF.
  • To analyze muscle function and energy metabolism polymorphisms in relation to VO2peak, FEV1, FVC, PImax, and muscular strength.
  • To compare findings in a CF cohort with a control group of healthy children.

Main Methods:

  • Genotyping of muscle function polymorphisms (e.g., ACE, AGT, ACTN3, NOS3) and energy metabolism polymorphisms (e.g., PPARGC1A, NRF1, NRF2).
  • Phenotypic assessment including VO2peak, FEV1, FVC, PImax, and muscular strength measurements.
  • Statistical analysis to determine correlations between polymorphisms and phenotypic traits in 66 children with CF and 113 healthy controls.

Main Results:

  • No significant correlations were found between the studied polymorphisms and PC or health phenotypes in children with CF.
  • Marginal associations were noted between NOS3 rs2070744 and VO2peak/FEV1, and PPARGC1A rs8192678 and FEV1 in the CF group.
  • Similar lack of major associations was observed in the control group, indicating no strong genetic influence from these polymorphisms.

Conclusions:

  • The investigated PC-related genetic polymorphisms do not appear to significantly affect physical capacity or health in children with cystic fibrosis.
  • Further research may be needed to identify other genetic factors or complex gene-environment interactions influencing PC in CF.
  • These findings suggest that current genetic targets may not be primary determinants of physical capacity deficits in pediatric CF populations.

More Related Videos

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

703
Standardized Measurement of Nasal Membrane Transepithelial Potential Difference NPD09:47

Standardized Measurement of Nasal Membrane Transepithelial Potential Difference NPD

Published on: September 13, 2018

19.7K

Related Concept Videos

Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
1.1K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
654
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
330
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
156
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
189
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
135